In this episode of the ATiO Podcast, we are honored to welcome Prof. David Hunter, a world-renowned leader in osteoarthritis research. As the Florance and Cope Chair of Rheumatology at the University of Sydney and Editor-in-Chief of Osteoarthritis and Cartilage, Professor Hunter has been instrumental in shaping our modern understanding of osteoarthritis.

Our conversation explores the complexity of OA—from disease mechanisms and current treatment strategies to the scientific and clinical challenges that have slowed therapeutic innovation. Professor Hunter shares insights into why osteoarthritis should be understood as a heterogeneous group of conditions, rather than a single disease entity.

We also discuss the role of prevention, lifestyle factors, emerging technologies, and international collaboration in advancing OA care. This episode offers a concise yet compelling look at how rigorous science and global cooperation are redefining the future of osteoarthritis management.

In this episode of the ATiO Podcast, we have the honor to welcome Prof. Ivan Martin, a world-renowned expert in tissue engineering and translational research. As Chair of the Department of Biomedicine at the University of Basel, Prof. Martin has spent over two decades advancing innovative solutions for musculoskeletal repair.

Our conversation dives into the intersection of basic science, clinical application, and entrepreneurship, highlighting the journey from lab bench to operating room. Prof. Martin shares key insights from his visionary work in cartilage regeneration, as well as the challenges of bridging academia and industry.

We also discuss the broader impact of regenerative therapies on healthcare systems, the importance of interdisciplinary collaboration, and the future of patient-specific treatment strategies. This episode offers a compelling look at how visionary research is transforming the landscape of orthopaedic care.

In this episode of the ATiO Podcast, we delve into the pioneering work of ZuriMED Technologies, a Swiss-based company specializing in advanced medical technologies for soft tissue repair. Founded in 2015 as a spin-off from the University of Zurich and ETH Zurich, ZuriMED has rapidly emerged at the forefront of orthopaedic innovation.

We are joined by Ronja Senn, Head of Sales at ZuriMED, who shares insights into the company’s mission to develop breakthrough technologies that enhance surgical outcomes and improve patient recovery. Under the leadership of Xiang Li, ZuriMED has introduced the Surgical-Fiberlock™ technology, a minimally invasive solution designed to revolutionize soft tissue repair.

In 2024, ZuriMED’s innovative approach earned them the prestigious ATiO Early-Stage Pitch Contest award, recognizing their significant contributions to the field. Ronja discusses the journey leading to this achievement, the challenges they’ve faced, and ZuriMED’s exciting plans for the future.